Share

September 2020; 7 (5) ArticleOpen Access

Painful trigeminal neuropathy associated with anti-Plexin D1 antibody

Takayuki Fujii, Ryo Yamasaki, Yukino Miyachi, Kyoko Iinuma, Yu Hashimoto, Noriko Isobe, Takuya Matsushita, Jun-ichi Kira
First published June 25, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000819
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
951

Share

Article Information

vol. 7 no. 5 e819
DOI: 
https://doi.org/10.1212/NXI.0000000000000819
PubMed: 
32587101
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received March 24, 2020
  • Accepted in final form May 14, 2020
  • First Published June 25, 2020.
Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Takayuki Fujii, MD, PhD,
    2. Ryo Yamasaki, MD, PhD,
    3. Yukino Miyachi, MSc,
    4. Kyoko Iinuma, MSc,
    5. Yu Hashimoto, MD,
    6. Noriko Isobe, MD, PhD,
    7. Takuya Matsushita, MD, PhD and
    8. Jun-ichi Kira, MD, PhD
  1. Takayuki Fujii, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Takeda Pharmaceutical Company, speaker honoraria (2)Eisai, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Mitsubishi Tanabe Pharma, (2) Osoegawa Neurology Clinic, (3) Bayer Yakuhin, Ltd., (4) the Japan Blood Products Organization

    Research Support, Government Entities:

    1. (1) the Japan Society for the Promotion of Science (JSPS) KAKENHI, grant number 19K17037, principal investigator, 2019-2020

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ryo Yamasaki, MD, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Clinical and experimental neuroimmunology, managing editor, since 2016 until now

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Yukino Miyachi, MSc,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Kyoko Iinuma, MSc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Yu Hashimoto, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Noriko Isobe, MD, PhD,
    7. Scientific Advisory Boards:

    1. (1) Commercial, Oxford Health Policy Forum CIC (scientific steering committee member for triMS-online)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis Pharma, speaker honoraria, (2) Alexion, speaker honoraria, (3) Takeda Pharmaceutical Company, speaker honoraria, (4) Biogen Japan, speaker honoraria, (5) Mitsubishi Tanabe Pharma, speaker honoraria.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Mitsubishi Tanabe Pharma, (2) Osoegawa Neurology Clinic, (3) Bayer Yakuhin, Ltd., (4) Japan Blood Products Organization.

    Research Support, Government Entities:

    1. (1) Grant-in-Aid for Research Activity Start-up (JSPS KAKENHI), 17H06938, Principal Investigator, 2017, and (2) Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI), 18K07529, Principal Investigator, 2018-2021.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Japan Multiple Sclerosis Society, and (2) Japan Intractable Disease Foundation.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Takuya Matsushita, MD, PhD and
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Bayer-Schering Pharma, Speaker honoraria (2) Mitsubishi Tanabe Pharma, Speaker honoraria (3) Biogen, Speaker honoraria, (4) Takeda Pharmaceutical Co. Ltd, Speaker honoraria (5) MSD K.K., Speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (KAKENHI) of Japan Society for the Promotion of Science, 17889552, Co- investigator, 2017 (2) Grant-in-Aid for Scientific Research (A), Grant-in-Aid for Scientific Research (KAKENHI) of Japan Society for the Promotion of Science, 16805610, Co- investigator, 2016-2017 (3) Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (KAKENHI) of Japan Society for the Promotion of Science, 15571065, Investigator, 2016-2017

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Jun-ichi Kira, MD, PhD
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. JK received speaking fees and/or honoraria from (1) Novartis Pharma, (2) Mitsubishi Tanabe Pharma, (3) Boehringer Ingelheim, (4) Teijin Pharma, (5) the Takeda Pharmaceutical Company, (6) Otsuka Pharmaceutical, (7) Astellas Pharma, (8) Pfizer Japan, and (9) Eisai.

    Editorial Boards:

    1. (1) Multiple Sclerosis Journal, Editorial Board Member, 2006-, (2) BMC Medicine, Editorial Board Member, 2010-, (3) Journal of the Neurological Sciences, Editorial Board Member, 2010-, (4) Multiple Sclerosis and Related Disorders, Editorial Board Member, Section Editor, 2011-, (5) PLOS ONE, Editorial Board Member, 2011-, (6) Frontiers in Immunology, Associate Editor, 2017-

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Biogen Japan (consultancy, since 2009)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis Pharma, (2) Boehringer Ingelheim, (3) Teijin Pharma, (4) Takeda Pharmaceutical Company, (5) Otsuka Pharmaceutical, (6) Astellas Pharma, (7) Pfizer Japan, (8) Eisai, (9) Dainippon-Sumitomo Pharmaceutical, (10) Tanabe- Mitsubishi Pharmaceutical, (11) Japan Blood Products Organization, (12) Bayer

    Research Support, Government Entities:

    1. (1) Grant-in-Aid for Scientific Research on Innovative Areas (MEXT KAKENHI), 25117012, Principal Investigator, 2013-2018, (2) Grant-in-Aid for Scientific Research on Innovative Areas (MEXT KAKENHI), 25117001, Co- investigator, 2013-2018, (3) Grant-in-Aid for Scientific Research on Innovative Areas (MEXT KAKENHI), 15K21729, Co-investigator, 2015-2018, (4) Grant-in-Aid for Challenging Exploratory Research (JSPS KAKENHI), 15K15341, Principal Investigator, 2015-2017, (5) Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI), 15K09343, Co- investigator, 2015-2018, (6) Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI), 16K10727, Co- investigator, 2016-2019, (7) Grant-in-Aid for Scientific Research (A) (JSPS KAKENHI), 16H02657, Principal Investigator, 2016-2019, (8) Grant-in-Aid for Challenging Exploratory Research (JSPS KAKENHI), 17K19663, Principal Investigator, 2017-2019, (9) Grant-in-Aid for Scientific Research (C) (JSPS KAKENHI), 18K07529, Co- investigator, 2018-2021, (10) Grant-in-Aid for Scientific Research (A) (JSPS KAKENHI), 19H01045, Principal Investigator, 2019-2022, (11) Practical Research Project for Rare/Intractable Diseases" from Japan Agency for Medical Research and Development, AMED, Japan, 16ek0109039h0003, Principal Investigator, 2016-2017, (12) Practical Research Project for Rare/Intractable Diseases" from Japan Agency for Medical Research and Development, AMED, Japan, 17ek0109115h0003, Principal Investigator, 2015-2018, (13) Practical Research Project for Rare/Intractable Diseases" from Japan Agency for Medical Research and Development, AMED, Japan, 18ek0109376h0001, Principal Investigator, 2018-2021, (14) Practical Research Project for Rare/Intractable Diseases" from Japan Agency for Medical Research and Development, AMED, Japan, 18ek0109308h0001, Principal Investigator, 2018-2021, (15) Health and Labour Sciences Research Grant on Intractable Diseases from the Ministry of Health, Labour, and Welfare, Japan, H29- Nanchitou(Nan)-Shitei-001, Co-investigator, 2017-2020, (16) Health and Labour Sciences Research Grant on Intractable Diseases from the Ministry of Health, Labour, and Welfare, Japan, H29-Nanchitou(Nan)-Ippan-043, Co- investigator, 2017-2020, (17) Health and Labour Sciences Research Grant on Intractable Diseases from the Ministry of Health, Labour, and Welfare, Japan, H29- Nanchitou(Nan)-Ippan-033, Co-investigator, 2017-2020, (18) Health and Labour Sciences Research Grant on Intractable Diseases from the Ministry of Health, Labour, and Welfare, Japan, H29-Nanchitou(Nan)-Ippan-009, Co- investigator, 2017-2020, (19) Health and Labour Sciences Research Grant on Intractable Diseases from the Ministry of Health, Labour, and Welfare, Japan, H28- Nanchitou(Nan)-Ippan-025, Principal Investigator, 2016- 2019, (20) Health and Labour Sciences Research Grant on Intractable Diseases from the Ministry of Health, Labour, and Welfare, Japan, H28-Nanchitou(Nan)-Ippan-018, Co-investigator, 2016-2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurological Therapeutics (T.F., N.I.), Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka; Department of Neurology (R.Y., Y.M., K.I., Y.H., T.M., J.K.), Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka; Translational Neuroscience Center (J.K.), Graduate School of Medicine, and School of Pharmacy at Fukuoka, International University of Health and Welfare, Ookawa, Fukuoka; and Department of Neurology (J.K.), Brain and Nerve Center, Fukuoka Central Hospital, International University of Health and Welfare, Chuou-ku, Japan.
  1. Correspondence
    Dr. Kira kira{at}neuro.med.kyushu-u.ac.jp
View Full Text

Article usage

Article usage: June 2020 to May 2022

AbstractFullPdfSource
Jun 20202417658Highwire
Jul 202012299100Highwire
Aug 2020713662Highwire
Sep 20201321033136Highwire
Oct 20201960067Highwire
Nov 2020725426Highwire
Dec 2020610217Highwire
Jan 202149336Highwire
Feb 202136021Highwire
Mar 202127124Highwire
Apr 202136724Highwire
May 202135823Highwire
Jun 202149070Highwire
Jul 202155730Highwire
Aug 202124830Highwire
Sep 202186727Highwire
Oct 202147934Highwire
Nov 202155625Highwire
Dec 202128436Highwire
Jan 202205023Highwire
Feb 202266816Highwire
Mar 202228618Highwire
Apr 202212614Highwire
May 202244434Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement